Разрешен к применению с 1995 года.
Видео о
Купить в
COVID-19 
По алфавиту
- A
- B
- C
- D
- E
- F
- G
- H
- I
- J
- K
- L
- M
- N
- O
- P
- Q
- R
- S
- T
- V
- W
- X
- Y
- Z
- І
- А
- Б
- В
- Г
- Д
- Е
- Ж
- З
- И
- К
- Л
- М
- Н
- О
- П
- Р
- С
- Т
- У
- Ф
- Х
- Ц
- Ч
- Ш
- Щ
- Э
- Ю
- Я
- Весь список
Warning: mb_strpos(): Empty delimiter in /var/www/u1363561/data/www/biotech.spb.ru/wp-content/plugins/code-snippets/php/snippet-ops.php(581) : eval()’d code(4) : eval()’d code on line 13
F Donskov, K M Bennedsgaard, H Von Der Maase, N Marcussen, R Fisker, J J Jensen, P Naredi, M Hokland
Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survivalBr J Cancer. 2002 Jul 15;87(2):194-201.
F Lauria, D Raspadori, M A Ventura, D Rondelli, P L Zinzani, F Gherlinzoni, M C Miggiano, M Fiacchini, G Rosti, S Rizzi, S Tura
Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin’s lymphoma patients after autologous bone marrow transplantationBone Marrow Transplant. 1996 Jul;18(1):79-85.
F Y Ahmed, G A Leonard, R A’Hern, A E Taylor, A Lorentzos, H Atkinson, J Moore, M C Nicolson, P G Riches, M E Gore
A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanomaBr J Cancer. 1996 Oct;74(7):1109-13.
Farace F, Mathiot C, Brandely M et al.
Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma.Clin Exp Immunol. 1990 Nov;82(2):194-9. doi: 10.1111/j.1365-2249.1990.tb05426.x. PMID: 2122928; PMCID: PMC1535125.
Farag S.S., Caligiuri M.A.
The Therapeutic Use of Natural-Killer Cells in Hematological Malignancies.Immunotherapy of Cancer. Cancer Drug Discovery and Development. Humana Press. pp 415-432.
Farag SS, George SL, Lee EJ et al.
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.Clin Cancer Res. 2002 Sep;8(9):2812-9.
Feng Wang, Shuxian Wang, Bo He et al. 
PDF
International Immunopharmacology, 97, 107663. doi:10.1016/j.intimp.2021.10766
Fogli M., Mavilio D., Brunetta E. et al.
Lysis of endogenously infected CD4+ T cell blasts by rIL-2 activated autologous natural killer cells from HIV-infected viremic individuals.PLoS Pathog. 2008 Jul 11;4(7):e1000101. doi: 10.1371/journal.ppat.1000101.
Fuentes E., Fuentes M., Alarcón M., Palomo I. PDF
Biomedical Sciences. An. Acad. Bras. Ciênc. 89 (1) • Mar 2017
В соответствии с п. 1 ст. 64 Федерального закона от 12.04.2010 № 61-ФЗ "Об обращении лекарственных средств" лекарственные препараты, находящиеся в обращении на территории Российской Федерации, подлежат мониторингу безопасности в целях выявления возможных негативных последствий их применения, предупреждения пациентов и их защиты от применения таких препаратов.